Status:
TERMINATED
Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.
Lead Sponsor:
BioMimetix JV, LLC
Conditions:
Acne Vulgaris
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is an exploratory Phase 2 trial of BMX-010 in patients with Acne Vulgaris which will be conducted in two parts.
Detailed Description
Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug in patients with Acne. Up to 60 subjects will be enrolled in this part. Part B is designed to b...
Eligibility Criteria
Inclusion
- Male or female, at least 18 years of age;
- A clinical diagnosis of mild to severe facial Acne Vulgaris; Subjects may also have acne at other body sites;
- Screening and Baseline IGA score \> 2 (greater than or equal to 2);
- Willing to refrain from using any topical or systemic treatments for inflammatory skin disease, other than the investigational product;
- Candidate for topical treatment of Acne;
- If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup.
- Females of child-bearing potential must have a negative urine pregnancy test within 48 hours prior to the first drug administration;
- Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the investigator (for example, oral contraceptive pills plus a barrier method) through the trial and for 1 month thereafter to be eligible for, and continue participation in, the study;
- Ability to complete the study in compliance with the protocol, including agreement in writing to apply study product only to the assigned areas; and
- Ability to understand and provide written informed consent.
Exclusion
- Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
- Use of androgen receptor blockers (such as spironolactone or flutamide);
- Severe cystic acne, acne conglobate, acne fulminans, or secondary acne;
- Use of phototherapy devices, energy-based devices, adhesive cleansing strips, or cosmetic procedures (e.g., facials, peeling, comedo extraction) in the past week;
- Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
- Prior or current concomitant therapies that would interfere with assessments in the study;
- Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
- Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products \[e.g., benzamycin\]), retinoids; other topical acne treatments (e.g., photodynamic therapy, medicated soaps such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium sulfacetamide) in the past 2 weeks;
- Oral retinoid use (e.g., isotretinoin) within 6 months prior to baseline or vitamin A supplements greater than 10,000 units/day within 6 months of baseline;
- Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
- Use of medicated make-up (including anti-aging make-up) throughout the study;
- Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact acne, 4) immunosuppressive agents, or immunomodulators;
- Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical acne treatments or 4) topical antibiotics;
- Use of medicated cleansers on the face (throughout the study);
- Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
- Systemic or skin infection requiring antimicrobial therapy;
- Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
- Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
- Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
- Active drug or alcohol dependence;
- Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
- Previous clinical trial participation for the indication being treated in this protocol.
Key Trial Info
Start Date :
January 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2020
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03752242
Start Date
January 3 2019
End Date
August 31 2020
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorado Skin Care
Englewood, Colorado, United States, 80113